Literature DB >> 12168095

Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol.

Axel Meye1, Udo Bilkenroth, Uta Schmidt, Susanne Füssel, Katja Robel, Andres M Melchior, Karen Blümke, Diana Pinkert, Frank Bartel, Clemens Linne, Helge Taubert, Manfred P Wirth.   

Abstract

The purpose of this study was to demonstrate the efficacy of an enrichment protocol for the detection of circulating carcinoma cells in the bloodstream of patients with various urologic cancers. Using 16-ml peripheral blood samples (BS) the mononuclear cells were isolated by density gradient centrifugation. The CD45 leukocyte depletion method based on a previous study was slightly modified and semi-automated by an immunomagnetic cell separation unit (autoMACS). Enriched tumor cells were analyzed on a single slide by cytokeratin (CK) immunocytochemistry. The number of recovered DU-145 prostate cancer cells in various spiking experiments was 70-88%. By the optimized tumor cell enrichment protocol 186 BS originated from 128 patients with different urologic cancers (60 prostate carcinoma, 34 bladder cancers, 24 renal cell carcinoma and 10 other tumors) were investigated before, during and after tumor surgery. In 59 BS from 52 patients on average 5 tumor cells were detected in each BS containing tumor cells. The median number of identified tumor cells was 8 cells per BS and patient. Tumor cells were found for the 3 tumor types with representative BS numbers in 29-39% of the investigated BS and in 38-53% of the affected patients. The detection rates increased in the order prostate carcinoma < renal cell carcinoma < bladder cancer. Surprisingly, in four bladder tumor cases with identified disseminated tumor cells in BS, the histopathological examination of the transurethral resection of bladder tumor specimens showed no evidence for tumor cells in situ but the affected patients had clinically known and histologically defined tumor residue or a bladder tumor recurrence during the follow-up. The semi-automated CD45 autoMACS depletion protocol for the enrichment and the detection of disseminated tumor cells in the peripheral bloodstream allows to study up to 20 BS per working day prospectively by one technician. The improved sensitivity and specificity might be of importance when applying the protocol to BS in future clinical studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168095

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  20 in total

1.  Perivascular human endometrial mesenchymal stem cells express pathways relevant to self-renewal, lineage specification, and functional phenotype.

Authors:  Trimble L B Spitzer; Angela Rojas; Zara Zelenko; Lusine Aghajanova; David W Erikson; Fatima Barragan; Michelle Meyer; John S Tamaresis; Amy E Hamilton; Juan C Irwin; Linda C Giudice
Journal:  Biol Reprod       Date:  2012-02-29       Impact factor: 4.285

2.  A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.

Authors:  Ronald Rodriguez; Shawn E Lupold; Ping Wu; Lori J Sokoll; Tarana A Kudrolli; Wasim H Chowdhury; Rong Ma; Minzhi M Liu
Journal:  Prostate       Date:  2014-07-25       Impact factor: 4.104

3.  Self-assembled magnetic filter for highly efficient immunomagnetic separation.

Authors:  David Issadore; Huilin Shao; Jaehoon Chung; Andita Newton; Mikael Pittet; Ralph Weissleder; Hakho Lee
Journal:  Lab Chip       Date:  2010-10-14       Impact factor: 6.799

Review 4.  Microchip-based detection of magnetically labeled cancer biomarkers.

Authors:  Melaku Muluneh; David Issadore
Journal:  Adv Drug Deliv Rev       Date:  2013-10-05       Impact factor: 15.470

Review 5.  Detection and isolation of circulating tumor cells in urologic cancers: a review.

Authors:  Robert D Loberg; Yaron Fridman; Brian A Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman; Kenneth J Pienta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 6.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

Review 7.  Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis.

Authors:  Pavlos Msaouel; Michael Koutsilieris
Journal:  BMC Cancer       Date:  2011-08-04       Impact factor: 4.430

8.  Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients.

Authors:  Zhian Liu; Alberto Fusi; Eva Klopocki; Alexander Schmittel; Ingeborg Tinhofer; Anika Nonnenmacher; Ulrich Keilholz
Journal:  J Transl Med       Date:  2011-05-19       Impact factor: 5.531

9.  Circulating and disseminated tumor cells in the management of advanced prostate cancer.

Authors:  Stephan Kruck; Georgios Gakis; Arnulf Stenzl
Journal:  Adv Urol       Date:  2011-08-21

10.  TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients.

Authors:  Nerymar Ortiz-Otero; Jocelyn R Marshall; Antonio Glenn; Jubin Matloubieh; Jean Joseph; Deepak M Sahasrabudhe; Edward M Messing; Michael R King
Journal:  BMC Cancer       Date:  2021-08-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.